To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

May 10, 2019

Today's Rundown

Featured Story

FibroGen sinks as roxadustat safety results confuse investors

FibroGen has reported top-line results from a pooled analysis of its phase 3 roxadustat safety data. Shares in FibroGen plummeted following the readout as the wording of the number-free statement and subsequent conference call raised concerns about the safety of the kidney disease drug.

Top Stories

Bayer puts up $150M to build West Coast cell culture facility

Bayer is investing $150 million to build a cell culture facility in California. The 40,000-square-foot site will support Bayer’s pipeline of oncology and cardiology programs when it comes online late in 2021.

Looking beyond cancer, Twentyeight-Seven Therapeutics bumps up series A to $82M+

With a series A extension of $17.75 million, Twentyeight-Seven will ramp up its cancer programs, develop programs aimed at other types of RNA and apply its work in disease areas other than cancer.

Harvard-born diabetes startup Semma reports advances in turning stem cells into insulin producers

Semma Therapeutics has faced an obstacle with its process of turning undifferentiated pluripotent stem cells into insulin-producing pancreatic beta cells: Only 30% of the resulting cells turn out to be beta cells. Now, a Semma-Harvard University team has figured out how to boost the proportion of beta cells emerging from their process to 80%.

EuroBiotech Report—Lundbeck, Pfizer ink deals; Confo, Promethera raise cash; and Bicycle

In this week's EuroBiotech Report, Lundbeck and Pfizer strike buyouts, Confo and Promethera raise cash and Bicycle hires staff.

FiercePharmaAsia—Takeda-Novartis Xiidra deal; Daiichi-AZ's HER2 ADC; Sun Pharma eyes China

Takeda sells dry-eye drug Xiidra to Novartis and offloads TachoSil patch to Johnson & Johnson. Daiichi Sankyo's HER2 antibody-drug conjugate, shared with AstraZeneca, meets its goal in a pivotal trial. Sun Pharma scouts for a partner to expand into China. And more.

Chutes & Ladders—Eisai installs new Alzheimer's leadership team

Eisai installs new Alzheimer's clinical trial leadership team; Insys founder found guilty in landmark opioid lawsuit; and Gilead's chief plots Kite CEO hire, plus organizational tweaks. Those moves plus more hirings, firings and retirings throughout the industry.

Resources

[Executive Summary] Achieving a Successful Drug Product Tech Transfer

Download the executive summary to learn key considerations for a successful technology transfer for manufacturing drug products, including a case study on overcoming challenges in a process transfer for a sterile diluent.

[Whitepaper] Choosing the Best Sterile Dosage Form for Phase I Clinical Supply Needs

Choosing the Best Sterile Dosage Form for Your Phase I Clinical Supply Needs.

[Whitepaper] Delivering oral solid dose product to Phase I Clinic in 14 weeks

Designed with speed & flexibility,Quick to Clinic™ for Oral Solid Dose helps deliver products to Phase I Clinic in as little as 14 weeks.

[Whitepaper] Agile Competitive Intelligence: A 3-Step Mobile Research Strategy

What is agile competitive intelligence, and how can help healthcare researchers stay ahead of the curve?

[Paid Marketplace] Accelerating DoD’s Fielding of Prototypes for Medical Countermeasures

MCS is currently seeking broad-based industry/academia collaboration on research and prototype work in technical areas related to developing medical countermeasures for the Joint Warfighter.

[Whitepaper] Now Companies Can Move Validated, Mission Critical Apps To The Cloud

Learn how the cloud can support the performance and security requirements for validated, mission-critical applications historically designed and implemented exclusively via on-premises deployment.

[Whitepaper] How the Internet of Things Creates Smarter Labs

Learn how cloud-connected IoT sensors are transforming operations in leading life science labs. Read our white paper “The Smart Lab”.

[Whitepaper] Personalized Test for Treatment Prediction in Depression

Total Brain Announces Personalized Test for Treatment Prediction in Depression with 80% Accuracy.

[Whitepaper] Observed Impact of Medication Price Transparency on Patients and Practices

Prescription price transparency technology is here – but is it making a difference? Find out HERE.

[Whitepaper] Redefining Your Value to Win Empowered Patients: Six Steps to Success

Every life sciences firm talks about patient-centricity, but are you doing what it takes to deliver?

[eBook] 2018 Weekly Compendium

The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry.

Events